INBRX-101: "INBRX-101 was well tolerated in this completed phase 1 study, with a safety profile consistent with those of approved pdAAT augmentation therapies"; Alpha-1 antitrypsin deficiency (Inhibrx) - Jun 14, 2023 - ATS 2023: "The 80- and 120-mg/kg Q3W doses of INBRX-101 maintained serum functional AAT levels above the lower limit of normal throughout the dosing period"
P1 data • Alpha-1 Antitrypsin Deficiency
|